Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients.
Adult
Aged
COVID-19
/ epidemiology
Coinfection
/ epidemiology
Female
Gram-Negative Bacteria
/ isolation & purification
Gram-Negative Bacterial Infections
/ epidemiology
Gram-Positive Bacteria
/ isolation & purification
Gram-Positive Bacterial Infections
/ epidemiology
Humans
Influenza A virus
/ isolation & purification
Influenza, Human
/ epidemiology
Israel
/ epidemiology
Length of Stay
Male
Middle Aged
Pandemics
Patient Admission
Retrospective Studies
SARS-CoV-2
/ isolation & purification
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 06 2021
16 06 2021
Historique:
received:
07
04
2021
accepted:
01
06
2021
entrez:
17
6
2021
pubmed:
18
6
2021
medline:
8
7
2021
Statut:
epublish
Résumé
Secondary bacterial infections are a potentially fatal complication of influenza infection. We aimed to define the impact of secondary bacterial infections on the clinical course and mortality in coronavirus disease 2019 (COVID-19) patients by comparison with influenza patients. COVID-19 (n = 642) and influenza (n = 742) patients, admitted to a large tertiary center in Israel and for whom blood or sputum culture had been taken were selected for this study. Bacterial culture results, clinical parameters, and death rates were compared. COVID-19 patients had higher rates of bacterial infections than influenza patients (12.6% vs. 8.7%). Notably, the time from admission to bacterial growth was longer in COVID-19 compared to influenza patients (4 (1-8) vs. 1 (1-3) days). Late infections (> 48 h after admission) with gram-positive bacteria were more common in COVID-19 patients (28% vs. 9.5%). Secondary infection was associated with a higher risk of death in both patient groups 2.7-fold (1.22-5.83) for COVID-19, and 3.09-fold (1.11-7.38) for Influenza). The association with death remained significant upon adjustment to age and clinical parameters in COVID-19 but not in influenza infection. Secondary bacterial infection is a notable complication associated with worse outcomes in COVID-19 than influenza patients. Careful surveillance and prompt antibiotic treatment may benefit selected patients.
Identifiants
pubmed: 34135459
doi: 10.1038/s41598-021-92220-0
pii: 10.1038/s41598-021-92220-0
pmc: PMC8209102
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12703Références
Microbes Infect. 2020 Oct;22(9):481-488
pubmed: 32561409
Lancet Respir Med. 2021 Mar;9(3):251-259
pubmed: 33341155
Am J Med. 2006 Jun;119(6 Suppl 1):S11-9; discussion S62-70
pubmed: 16735146
Nat Rev Microbiol. 2014 Apr;12(4):252-62
pubmed: 24590244
Front Microbiol. 2017 Jun 23;8:1041
pubmed: 28690590
Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11
pubmed: 15793102
J Infect. 2012 Sep;65(3):223-30
pubmed: 22543245
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
J Immunol. 2013 Sep 1;191(5):2047-52
pubmed: 23964104
J Infect. 2009 Sep;59 Suppl 1:S4-16
pubmed: 19766888
J Infect Dis. 2008 Oct 1;198(7):962-70
pubmed: 18710327
Front Immunol. 2020 Feb 13;11:117
pubmed: 32117268
mBio. 2016 Dec 13;7(6):
pubmed: 27965455
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
PLoS One. 2020 Nov 23;15(11):e0242533
pubmed: 33226995